Kennichi Kakudo | Molecular Diagnostics | Best Researcher Award

Published on by Biotechnology Scientist

Best Researcher Award

Kennichi Kakudo — Kindai University Nara Hospital, Japan

Kennichi Kakudo
Affiliation Kindai University Nara Hospital
Country Japan
Scopus ID 57195026520
Documents 389
Citations 12,733
h-index 59
Subject Area Molecular Diagnostics
Event Biotechnology Scientist Awards
Google Scholar uyM0bJAAAAAJ

Kennichi Kakudo is a Japanese academic pathologist and molecular diagnostics researcher recognized for his extensive contributions to thyroid pathology, endocrine tumor classification, and diagnostic standardization. His research has significantly influenced the international understanding of thyroid neoplasms and molecular pathology frameworks in endocrine oncology.[1] Through decades of scholarly activity, Kakudo has contributed to the refinement of diagnostic criteria for thyroid carcinomas and has participated in internationally recognized classification initiatives.[2]

Abstract

Kennichi Kakudo has established a distinguished academic profile in endocrine pathology and molecular diagnostics, particularly in thyroid tumor classification and diagnostic pathology. His research portfolio includes investigations into follicular variants of papillary thyroid carcinoma, molecular diagnostic testing, observer variability in thyroid lesion interpretation, and standardized classification systems for thyroid neoplasms.[3] His collaborative work has contributed to international consensus guidelines and has supported evidence-based approaches intended to reduce overtreatment in indolent thyroid tumors.[4]

Keywords

Molecular Diagnostics, Thyroid Pathology, Endocrine Oncology, Papillary Thyroid Carcinoma, Tumor Classification, Histopathology, Diagnostic Standardization, Biomarker Research, Thyroid Neoplasms, Pathological Diagnostics

Introduction

The field of thyroid pathology has undergone substantial refinement through advances in molecular diagnostics and histopathological classification systems. Researchers such as Kennichi Kakudo have contributed to the development of reproducible diagnostic criteria that improve clinical decision-making and reduce unnecessary therapeutic interventions.[2] His collaborative studies have addressed observer variation in follicular thyroid lesions and have influenced the adoption of internationally accepted classification terminology.[5]

Kakudo’s work spans diagnostic pathology, molecular biomarkers, endocrine tumor classification, and translational applications in surgical pathology. His academic contributions are widely cited within endocrine oncology and pathology literature.[1]

Research Profile

Kennichi Kakudo is affiliated with Kindai University Nara Hospital and has also been associated with Izumi City General Hospital in Japan. His Scopus author profile reports 389 indexed documents, more than 12,700 citations, and an h-index of 59, reflecting sustained academic productivity and influence within endocrine pathology research.[1]

  • Primary specialization in molecular diagnostics and endocrine pathology.
  • Extensive contributions to thyroid carcinoma classification systems.
  • Participation in collaborative international pathology consensus initiatives.
  • Research involvement in biomarker-based diagnostic methodologies.
  • Significant publication impact within pathology and oncology journals.

Research Contributions

Kakudo contributed to the landmark nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma, an initiative intended to reduce overtreatment of indolent tumors through more precise pathological classification.[3] This work represented a significant paradigm shift in endocrine oncology and diagnostic pathology.

His collaborative role in the Turin proposal established uniform diagnostic criteria for poorly differentiated thyroid carcinoma, improving diagnostic consistency across pathology laboratories and clinical settings.[2]

Additional investigations examined observer variability in follicular thyroid lesions, helping to identify limitations in diagnostic reproducibility and supporting the development of standardized interpretation approaches.[5]

  • Development of standardized thyroid tumor diagnostic criteria.
  • Research in molecular testing for thyroid nodules.
  • Studies on observer agreement in endocrine pathology.
  • Advancement of translational molecular pathology methodologies.
  • Contribution to WHO thyroid tumor classification updates.

Publications

Selected influential publications associated with Kennichi Kakudo include the following:

  1. “Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors.” JAMA Oncology, 2016.
  2. “Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach.” The American Journal of Surgical Pathology, 2007.
  3. “Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.” The American Journal of Surgical Pathology, 2004.
  4. “Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach.” Endocrinology and Metabolism, 2022.
  5. “Impact of Molecular Testing on Surgical Decision-Making in Indeterminate Thyroid Nodules: A Global Meta-Analysis Across Test Generations.” Endocrine Pathology, 2026.

Research Impact

The academic impact of Kennichi Kakudo is reflected through high citation metrics and sustained international recognition in pathology and endocrine oncology literature.[1] His publications have been widely referenced in discussions concerning thyroid tumor nomenclature, molecular pathology, and standardized diagnostic frameworks.[4]

His work has contributed to reducing overtreatment in thyroid cancer management by promoting refined classification systems and molecularly informed pathology practices. These contributions have relevance for surgical decision-making, pathology reporting consistency, and evidence-based clinical management.[3]

Award Suitability

Kennichi Kakudo demonstrates strong suitability for recognition within the Biotechnology Scientist Awards due to his sustained contributions to molecular diagnostics, endocrine pathology, and translational oncology research.[1] His collaborative involvement in internationally influential diagnostic frameworks and WHO classification updates reflects substantial scholarly engagement and clinical relevance.[4]

  • Extensive international publication record.
  • High citation impact in pathology and oncology.
  • Contributions to global diagnostic standardization.
  • Influence on molecular diagnostic methodologies.
  • Long-standing academic and clinical research engagement.

Conclusion

Kennichi Kakudo has contributed significantly to the advancement of thyroid pathology and molecular diagnostics through internationally recognized research and collaborative classification initiatives. His scholarly work has influenced diagnostic reproducibility, tumor classification systems, and evidence-based endocrine oncology practices.[2] The breadth of his research activity and citation impact supports his recognition within the context of scientific and biotechnology-related academic awards.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Kennichi Kakudo, Author ID 57195026520. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195026520
  2. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, et al. (2007). Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. The American Journal of Surgical Pathology.
  3. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, et al. (2016). Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncology.
    https://doi.org/10.1001/jamaoncol.2016.0386
  4. Jung CK, Bychkov A, Kakudo K. (2022). Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinology and Metabolism.
  5. Kennichi Kakudo 1, Yanhua Bai, Zhiyan Liu, Takashi Ozaki 2012 Encapsulated papillary thyroid carcinoma, follicular variant: a misnomer.
    https://pubmed.ncbi.nlm.nih.gov/

Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Published on by Biotechnology Scientist

Prof. Dr. Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Director at University of Utah-Huntsman Cancer Institute | United States

Dr. Manish Kohli is a distinguished physician-scientist and academician whose career spans over two decades, focusing on transforming cancer care through convergence science and translational oncology. He currently serves as a tenured professor in the Department of Medicine at the University of Utah and holds the Jack and Hazel Robertson Presidential Endowed Chair in Cancer Research at the Huntsman Cancer Institute. Known for integrating clinical insight with computational approaches, Dr. Kohli leads multi-disciplinary research to develop personalized treatment strategies, particularly in prostate cancer. He is also the Director of the Physician Scientist Training Program, where he mentors emerging physician-researchers in internal medicine.

Profile

Scopus

Orcid

Education

Dr. Kohli received his M.B.B.S. from Maulana Azad Medical College, University of Delhi, followed by a residency in internal medicine at Cook County Hospital in Chicago. He completed his hematology and oncology fellowship training at the University of Arkansas for Medical Sciences. To enhance his skills in clinical research and data science, he pursued advanced training through certificate programs at Harvard Medical School, focusing on clinical trials and artificial intelligence in healthcare. His educational foundation reflects a seamless blend of clinical proficiency and data-driven research expertise.

Experience

Dr. Kohli has held academic and clinical leadership roles at several renowned institutions, including Mayo Clinic, H. Lee Moffitt Cancer Center, University of Rochester, and the University of Illinois at Urbana-Champaign. He served as Vice-Chair in the Department of Genitourinary Oncology and Director of Personalized Medicine at Moffitt Cancer Center. At Mayo Clinic, he was Professor of Oncology and a consultant in both medical oncology and urology. His administrative experience includes directing fellowship programs, co-chairing disease-specific working groups, serving on IRBs, and contributing to molecular pathology committees. His current role at the University of Utah includes active involvement in faculty advisory and innovation committees, shaping strategic research and training agendas.

Research interest

Dr. Kohli’s research lies at the intersection of cancer biology, bioengineering, and computational sciences. His major focus is on developing ultra-sensitive liquid biopsy technologies and fusing them with omics-based data to generate predictive biomarkers for therapy selection. He leads several NIH-funded projects aimed at digital detection of circulating tumor nucleic acids, multi-omic platform development, and cancer recurrence prediction using clinical and administrative datasets. His team utilizes machine learning algorithms to support biomarker-guided clinical trial designs and optimize therapeutic decisions. Another vital component of his research involves health economic outcomes to address disparities and costs in oncology care.

Award

Dr. Kohli has received numerous recognitions for his scientific contributions and mentorship. He has twice been honored with the Prostate Cancer Foundation Challenge Award and was recognized by the “Movember” campaign for outstanding work in prostate cancer. His teaching excellence has been acknowledged by institutions such as Mayo Clinic, and he has received awards from the VA system for clinical service. Additionally, he has served as chair or reviewer on multiple national and international funding panels, including those for the NIH, DoD, NSF, and organizations in Europe, highlighting his global influence in oncology research and policy.

Publication

Dr. Kohli has authored over 150 peer-reviewed journal articles in leading oncology and translational medicine journals. Representative publications include:

Title: 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies
Year: 2025
Citation: 02

Title: Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer
Year: 2025

Title: Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
Year: 2025

Title: Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
Year: 2025

Title: Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer
Year: 2025
Citation: 01

Title: Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer
Year: 2024
Citation: 01

Conclusion

Dr. Manish Kohli’s career embodies the synergy of clinical excellence, data science, and academic leadership. Through his ongoing work in convergence oncology, he continues to pioneer innovative diagnostics and treatment models that personalize and improve cancer care. His leadership in education, editorial roles, and multi-institutional research reflects a commitment to integrating translational science with real-world impact. With his multidisciplinary approach and focus on health equity, Dr. Kohli remains a transformative figure in advancing the future of precision oncology.